Onconova Therapeutics, Inc.
NASDAQ:ONTX
0.9953 (USD) • At close April 2, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.226 | 0.226 | 0.226 | 0.231 | 2.183 | 1.228 | 0.787 | 5.546 | 11.456 | 0.8 | 4.753 | 46.19 | 1.487 |
| Cost of Revenue
| -225,999.774 | 0.014 | 0.014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 226,000 | 0.212 | 0.212 | 0.231 | 2.183 | 1.228 | 0.787 | 5.546 | 11.456 | 0.8 | 4.753 | 46.19 | 1.487 |
| Gross Profit Ratio
| 1,000,000 | 0.938 | 0.938 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 11.43 | 11.406 | 7.297 | 16.898 | 15.537 | 16.924 | 19.119 | 20.071 | 25.895 | 49.425 | 50.182 | 52.762 | 22.624 |
| General & Administrative Expenses
| 9.094 | 8.447 | 9.425 | 8.326 | 8.345 | 7.586 | 7.405 | 9.178 | 9.533 | 15.119 | 16.793 | 0 | 6.436 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.094 | 8.447 | 9.425 | 8.326 | 8.345 | 7.586 | 7.405 | 9.178 | 9.533 | 15.119 | 16.793 | 15.707 | 6.436 |
| Other Expenses
| 1.35 | 0.663 | 0.012 | 0.048 | 0.143 | 1.151 | 0.03 | 0 | -0.035 | -0.05 | 0.063 | 15.707 | 0.011 |
| Operating Expenses
| 20.524 | 19.853 | 16.722 | 25.224 | 23.882 | 24.51 | 26.524 | 29.249 | 35.428 | 64.544 | 66.975 | 68.469 | 29.06 |
| Operating Income
| -20.298 | -19.627 | -16.496 | -24.993 | -21.699 | -23.282 | -25.737 | -23.703 | -23.972 | -63.744 | -62.222 | -22.279 | -27.573 |
| Operating Income Ratio
| -89.814 | -86.845 | -72.991 | -108.195 | -9.94 | -18.959 | -32.703 | -4.274 | -2.093 | -79.68 | -13.091 | -0.482 | -18.543 |
| Total Other Income Expenses Net
| 1.35 | 0.663 | 0.333 | -0.16 | 0.206 | 2.748 | 1.658 | 4.05 | -0.035 | -0.032 | 0.101 | -7.633 | 1.279 |
| Income Before Tax
| -18.948 | -18.964 | -16.163 | -25.153 | -21.493 | -20.534 | -24.079 | -19.653 | -24.007 | -63.776 | -62.121 | -29.912 | -26.294 |
| Income Before Tax Ratio
| -83.841 | -83.912 | -71.518 | -108.887 | -9.846 | -16.721 | -30.596 | -3.544 | -2.096 | -79.72 | -13.07 | -0.648 | -17.683 |
| Income Tax Expense
| 0 | -0.663 | -0.335 | 0.004 | 0.01 | -0.124 | 0.013 | 0.014 | 0.016 | 0.019 | 0.435 | 8.608 | 0.03 |
| Net Income
| -18.948 | -18.301 | -15.828 | -25.157 | -21.503 | -20.573 | -24.092 | -19.667 | -23.979 | -63.682 | -62.543 | -29.912 | -26.294 |
| Net Income Ratio
| -83.841 | -80.978 | -70.035 | -108.905 | -9.85 | -16.753 | -30.612 | -3.546 | -2.093 | -79.603 | -13.159 | -0.648 | -17.683 |
| EPS
| -0.9 | -0.88 | -0.94 | -2.17 | -22.42 | -53.37 | -602.28 | -999.64 | -2,372.75 | -6,617.69 | -13,284.41 | -4,357.81 | -3,830.71 |
| EPS Diluted
| -0.9 | -0.88 | -0.94 | -2.17 | -22.42 | -53.37 | -602.28 | -999.64 | -2,372.75 | -6,617.69 | -13,284.41 | -4,357.81 | -3,830.71 |
| EBITDA
| -20.282 | -19.627 | -16.817 | -24.785 | -21.762 | -24.879 | -27.365 | -27.657 | -23.822 | -63.712 | -62.159 | -21.96 | -27.246 |
| EBITDA Ratio
| -89.743 | -86.845 | -74.412 | -107.294 | -9.969 | -20.26 | -34.771 | -4.987 | -2.079 | -79.64 | -13.078 | -0.475 | -18.323 |